+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Compounding Pharmacies Market By Therapeutic Area, By Route of Administration, By Sterility: Global Opportunity Analysis and Industry Forecast, 2021-2031

  • PDF Icon

    Report

  • 268 Pages
  • July 2022
  • Region: Global
  • Allied Market Research
  • ID: 5670908
Description Jump to:
Compounding is preparation of a custom formulation of a medication to fit a unique need of a patient that cannot be met with commercially available products. They are able to make unique medications for each person as some people need drugs that are not available on the market. Compounding pharmacies can be of assistance in this situation since there are several potential causes for this need. Compounding pharmacies can create sterile and non-sterile chemicals. While some pharmacies may provide services for both types of compounding, others may only specialize in one. Injections, ocular drops, and infusions are examples of dosage forms that contain sterile substances.

The major factors that drive the growth of the global compound pharmacies market include increase in prevalence of chronic disease, high adoption of non-sterile medication, increase in old age population and improved life expectancy. In addition, growing drug failure rate, increase in popularity of personalized medicine and massive drug shortage across the globe is further propel the market growth during forecast period. However, increase in restrictions on manufacturing of complex formulation is likely to restrain the growth of the compounding pharmacies market during the forecast period. Conversely, growth potential of emerging economies is anticipated to provide numerous opportunities for market growth during the forecast period.

The compounding pharmacies market is segmented into therapeutic area, route of administration, sterility, and region. According to therapeutic area, the market is categorized into pain management, hormone replacement, dermal disorder, nutritional supplement and others. On the basis of route of administration, it is segmented into oral, topical and others. By end user, it is segregated into sterile compounding drugs and non-sterile compounding drugs. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include the Advance Pharmacy, Athenex pharma, B. Braun Melsungen AG, Dougherty's Pharmacy, Inc., Fresenius SE and Co. KGaA, Institutional pharmacy solutions, ITC compounding pharmacy, The McGuff Companies, Inc., Nephron pharmaceuticals, New Compounding Pharma, Olympia Pharmaceuticals, Panacea biomatx, Pencol compounding pharmacy, Perrigo Company plc, Rx express compounding pharmacy, RX3 compounding pharmacy, Valor Compounding Pharmacy.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the compounding pharmacies market analysis from 2021 to 2031 to identify the prevailing compounding pharmacies market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the compounding pharmacies market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global compounding pharmacies market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Therapeutic Area

  • Pain Management
  • Hormone Replacement Therapy
  • Dermal Disorders
  • Nutritional Supplements
  • Others

By Route of Administration

  • Oral
  • Topical
  • Others

By Sterility

  • Non-Sterile Compounding Drugs
  • Distribution Channel
  • Hospital Pharmacy
  • Compounding Pharmacy
  • Others
  • Sterile Compounding Drugs
  • Distribution Channel
  • Hospital Pharmacy
  • Compounding Pharmacy
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Italy
  • Spain
  • Rest of Europe
  • Germany
  • France
  • UK
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players

  • Advanced Pharmacy
  • Athenex Pharma Solutions
  • B. Braun Melsungen AG
  • Dougherty's Pharmacy, Inc.
  • Fresenius SE and Co. KGaA
  • Institutional pharmacy solutions
  • ITC compounding pharmacy
  • McGuff Companies, Inc.
  • Nephron pharmaceuticals
  • New Compounding Pharma
  • Olympia Compounding Pharmacy
  • Panacea Biomatx Inc (Triangle Compounding Pharmacy)
  • Pencol compounding pharmacy
  • Perrigo Company Plc (Fagron)
  • Rx express compounding pharmacy
  • RX3 compounding pharmacy
  • Valor Compounding Pharmacy

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA
4.1 Overview
4.1.1 Market size and forecast
4.2 Pain Management
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Hormone Replacement Therapy
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Dermal Disorders
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Nutritional Supplements
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Others
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
CHAPTER 5: COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Oral
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Topical
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Others
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: COMPOUNDING PHARMACIES MARKET, BY STERILITY
6.1 Overview
6.1.1 Market size and forecast
6.2 Non-Sterile Compounding Drugs
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.2.4 Non-Sterile Compounding Drugs Compounding Pharmacies Market by Distribution Channel
6.3 Sterile Compounding Drugs
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.3.4 Sterile Compounding Drugs Compounding Pharmacies Market by Distribution Channel
CHAPTER 7: COMPOUNDING PHARMACIES MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Therapeutic Area
7.2.3 North America Market size and forecast, by Route of Administration
7.2.4 North America Market size and forecast, by Sterility
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Therapeutic Area
7.2.5.1.2 Market size and forecast, by Route of Administration
7.2.5.1.3 Market size and forecast, by Sterility
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Therapeutic Area
7.2.5.2.2 Market size and forecast, by Route of Administration
7.2.5.2.3 Market size and forecast, by Sterility
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Therapeutic Area
7.2.5.3.2 Market size and forecast, by Route of Administration
7.2.5.3.3 Market size and forecast, by Sterility
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Therapeutic Area
7.3.3 Europe Market size and forecast, by Route of Administration
7.3.4 Europe Market size and forecast, by Sterility
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Therapeutic Area
7.3.5.1.2 Market size and forecast, by Route of Administration
7.3.5.1.3 Market size and forecast, by Sterility
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Therapeutic Area
7.3.5.2.2 Market size and forecast, by Route of Administration
7.3.5.2.3 Market size and forecast, by Sterility
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Therapeutic Area
7.3.5.3.2 Market size and forecast, by Route of Administration
7.3.5.3.3 Market size and forecast, by Sterility
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Therapeutic Area
7.3.5.4.2 Market size and forecast, by Route of Administration
7.3.5.4.3 Market size and forecast, by Sterility
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Therapeutic Area
7.3.5.5.2 Market size and forecast, by Route of Administration
7.3.5.5.3 Market size and forecast, by Sterility
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Therapeutic Area
7.3.5.6.2 Market size and forecast, by Route of Administration
7.3.5.6.3 Market size and forecast, by Sterility
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Therapeutic Area
7.4.3 Asia-Pacific Market size and forecast, by Route of Administration
7.4.4 Asia-Pacific Market size and forecast, by Sterility
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Therapeutic Area
7.4.5.1.2 Market size and forecast, by Route of Administration
7.4.5.1.3 Market size and forecast, by Sterility
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Therapeutic Area
7.4.5.2.2 Market size and forecast, by Route of Administration
7.4.5.2.3 Market size and forecast, by Sterility
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Therapeutic Area
7.4.5.3.2 Market size and forecast, by Route of Administration
7.4.5.3.3 Market size and forecast, by Sterility
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Therapeutic Area
7.4.5.4.2 Market size and forecast, by Route of Administration
7.4.5.4.3 Market size and forecast, by Sterility
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Therapeutic Area
7.4.5.5.2 Market size and forecast, by Route of Administration
7.4.5.5.3 Market size and forecast, by Sterility
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Therapeutic Area
7.4.5.6.2 Market size and forecast, by Route of Administration
7.4.5.6.3 Market size and forecast, by Sterility
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Therapeutic Area
7.5.3 LAMEA Market size and forecast, by Route of Administration
7.5.4 LAMEA Market size and forecast, by Sterility
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Therapeutic Area
7.5.5.1.2 Market size and forecast, by Route of Administration
7.5.5.1.3 Market size and forecast, by Sterility
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Therapeutic Area
7.5.5.2.2 Market size and forecast, by Route of Administration
7.5.5.2.3 Market size and forecast, by Sterility
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Therapeutic Area
7.5.5.3.2 Market size and forecast, by Route of Administration
7.5.5.3.3 Market size and forecast, by Sterility
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Therapeutic Area
7.5.5.4.2 Market size and forecast, by Route of Administration
7.5.5.4.3 Market size and forecast, by Sterility
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Advanced Pharmacy
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Athenex Pharma Solutions
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 B. Braun Melsungen AG
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Dougherty's Pharmacy, Inc.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Fresenius SE and Co. KGaA
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Institutional pharmacy solutions
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 ITC compounding pharmacy
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 McGuff Companies, Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Nephron pharmaceuticals
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 New Compounding Pharma
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Olympia Compounding Pharmacy
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Panacea Biomatx Inc (Triangle Compounding Pharmacy)
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
9.13 Pencol compounding pharmacy
9.13.1 Company overview
9.13.2 Company snapshot
9.13.3 Operating business segments
9.13.4 Product portfolio
9.13.5 Business performance
9.13.6 Key strategic moves and developments
9.14 Perrigo Company Plc (Fagron)
9.14.1 Company overview
9.14.2 Company snapshot
9.14.3 Operating business segments
9.14.4 Product portfolio
9.14.5 Business performance
9.14.6 Key strategic moves and developments
9.15 Rx express compounding pharmacy
9.15.1 Company overview
9.15.2 Company snapshot
9.15.3 Operating business segments
9.15.4 Product portfolio
9.15.5 Business performance
9.15.6 Key strategic moves and developments
9.16 RX3 compounding pharmacy
9.16.1 Company overview
9.16.2 Company snapshot
9.16.3 Operating business segments
9.16.4 Product portfolio
9.16.5 Business performance
9.16.6 Key strategic moves and developments
9.17 Valor Compounding Pharmacy
9.17.1 Company overview
9.17.2 Company snapshot
9.17.3 Operating business segments
9.17.4 Product portfolio
9.17.5 Business performance
9.17.6 Key strategic moves and developments
List of Tables
Table 1. Global Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 2. Compounding Pharmacies Market Size, for Pain Management, by Region, 2021-2031 ($Million)
Table 3. Compounding Pharmacies Market for Pain Management, by Country, 2021-2031 ($Million)
Table 4. Compounding Pharmacies Market Size, for Hormone Replacement Therapy, by Region, 2021-2031 ($Million)
Table 5. Compounding Pharmacies Market for Hormone Replacement Therapy, by Country, 2021-2031 ($Million)
Table 6. Compounding Pharmacies Market Size, for Dermal Disorders, by Region, 2021-2031 ($Million)
Table 7. Compounding Pharmacies Market for Dermal Disorders, by Country, 2021-2031 ($Million)
Table 8. Compounding Pharmacies Market Size, for Nutritional Supplements, by Region, 2021-2031 ($Million)
Table 9. Compounding Pharmacies Market for Nutritional Supplements, by Country, 2021-2031 ($Million)
Table 10. Compounding Pharmacies Market Size, for Others, by Region, 2021-2031 ($Million)
Table 11. Compounding Pharmacies Market for Others, by Country, 2021-2031 ($Million)
Table 12. Global Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 13. Compounding Pharmacies Market Size, for Oral, by Region, 2021-2031 ($Million)
Table 14. Compounding Pharmacies Market for Oral, by Country, 2021-2031 ($Million)
Table 15. Compounding Pharmacies Market Size, for Topical, by Region, 2021-2031 ($Million)
Table 16. Compounding Pharmacies Market for Topical, by Country, 2021-2031 ($Million)
Table 17. Compounding Pharmacies Market Size, for Others, by Region, 2021-2031 ($Million)
Table 18. Compounding Pharmacies Market for Others, by Country, 2021-2031 ($Million)
Table 19. Global Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 20. Compounding Pharmacies Market Size, for Non-Sterile Compounding Drugs, by Region, 2021-2031 ($Million)
Table 21. Compounding Pharmacies Market for Non-Sterile Compounding Drugs, by Country, 2021-2031 ($Million)
Table 22. Global Non-Sterile Compounding Drugs Compounding Pharmacies Market, by Distribution Channel, 2021-2031 ($Million)
Table 23. Compounding Pharmacies Market Size, for Sterile Compounding Drugs, by Region, 2021-2031 ($Million)
Table 24. Compounding Pharmacies Market for Sterile Compounding Drugs, by Country, 2021-2031 ($Million)
Table 25. Global Sterile Compounding Drugs Compounding Pharmacies Market, by Distribution Channel, 2021-2031 ($Million)
Table 26. Compounding Pharmacies Market, by Region, 2021-2031 ($Million)
Table 27. North America Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 28. North America Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 29. North America Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 30. North America Compounding Pharmacies Market, by Country, 2021-2031 ($Million)
Table 31. U.S. Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 32. U.S. Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 33. U.S. Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 34. Canada Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 35. Canada Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 36. Canada Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 37. Mexico Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 38. Mexico Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 39. Mexico Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 40. Europe Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 41. Europe Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 42. Europe Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 43. Europe Compounding Pharmacies Market, by Country, 2021-2031 ($Million)
Table 44. Germany Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 45. Germany Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 46. Germany Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 47. France Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 48. France Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 49. France Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 50. UK Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 51. UK Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 52. UK Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 53. Italy Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 54. Italy Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 55. Italy Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 56. Spain Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 57. Spain Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 58. Spain Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 59. Rest of Europe Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 60. Rest of Europe Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 61. Rest of Europe Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 62. Asia-Pacific Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 63. Asia-Pacific Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 64. Asia-Pacific Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 65. Asia-Pacific Compounding Pharmacies Market, by Country, 2021-2031 ($Million)
Table 66. Japan Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 67. Japan Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 68. Japan Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 69. China Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 70. China Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 71. China Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 72. India Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 73. India Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 74. India Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 75. Australia Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 76. Australia Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 77. Australia Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 78. South Korea Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 79. South Korea Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 80. South Korea Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 81. Rest of Asia-Pacific Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 82. Rest of Asia-Pacific Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 83. Rest of Asia-Pacific Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 84. LAMEA Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 85. LAMEA Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 86. LAMEA Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 87. LAMEA Compounding Pharmacies Market, by Country, 2021-2031 ($Million)
Table 88. Brazil Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 89. Brazil Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 90. Brazil Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 91. Saudi Arabia Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 92. Saudi Arabia Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 93. Saudi Arabia Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 94. South Africa Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 95. South Africa Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 96. South Africa Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 97. Rest of LAMEA Compounding Pharmacies Market, by Therapeutic Area, 2021-2031 ($Million)
Table 98. Rest of LAMEA Compounding Pharmacies Market, by Route of Administration, 2021-2031 ($Million)
Table 99. Rest of LAMEA Compounding Pharmacies Market, by Sterility, 2021-2031 ($Million)
Table 100. Advanced Pharmacy: Company Snapshot
Table 101. Advanced Pharmacy: Operating Segments
Table 102. Advanced Pharmacy: Product Portfolio
Table 103. Advanced Pharmacy: Net Sales
Table 104. Advanced Pharmacy: Key Stratergies
Table 105. Athenex Pharma Solutions: Company Snapshot
Table 106. Athenex Pharma Solutions: Operating Segments
Table 107. Athenex Pharma Solutions: Product Portfolio
Table 108. Athenex Pharma Solutions: Net Sales
Table 109. Athenex Pharma Solutions: Key Stratergies
Table 110. B. Braun Melsungen Ag: Company Snapshot
Table 111. B. Braun Melsungen Ag: Operating Segments
Table 112. B. Braun Melsungen Ag: Product Portfolio
Table 113. B. Braun Melsungen Ag: Net Sales
Table 114. B. Braun Melsungen Ag: Key Stratergies
Table 115. Dougherty's Pharmacy, Inc.: Company Snapshot
Table 116. Dougherty's Pharmacy, Inc.: Operating Segments
Table 117. Dougherty's Pharmacy, Inc.: Product Portfolio
Table 118. Dougherty's Pharmacy, Inc.: Net Sales
Table 119. Dougherty's Pharmacy, Inc.: Key Stratergies
Table 120. Fresenius Se and Co. KGaA: Company Snapshot
Table 121. Fresenius Se and Co. KGaA: Operating Segments
Table 122. Fresenius Se and Co. KGaA: Product Portfolio
Table 123. Fresenius Se and Co. KGaA: Net Sales
Table 124. Fresenius Se and Co. KGaA: Key Stratergies
Table 125. Institutional Pharmacy Solutions: Company Snapshot
Table 126. Institutional Pharmacy Solutions: Operating Segments
Table 127. Institutional Pharmacy Solutions: Product Portfolio
Table 128. Institutional Pharmacy Solutions: Net Sales
Table 129. Institutional Pharmacy Solutions: Key Stratergies
Table 130. Itc Compounding Pharmacy: Company Snapshot
Table 131. Itc Compounding Pharmacy: Operating Segments
Table 132. Itc Compounding Pharmacy: Product Portfolio
Table 133. Itc Compounding Pharmacy: Net Sales
Table 134. Itc Compounding Pharmacy: Key Stratergies
Table 135. Mcguff Companies, Inc.: Company Snapshot
Table 136. Mcguff Companies, Inc.: Operating Segments
Table 137. Mcguff Companies, Inc.: Product Portfolio
Table 138. Mcguff Companies, Inc.: Net Sales
Table 139. Mcguff Companies, Inc.: Key Stratergies
Table 140. Nephron Pharmaceuticals: Company Snapshot
Table 141. Nephron Pharmaceuticals: Operating Segments
Table 142. Nephron Pharmaceuticals: Product Portfolio
Table 143. Nephron Pharmaceuticals: Net Sales
Table 144. Nephron Pharmaceuticals: Key Stratergies
Table 145. New Compounding Pharma: Company Snapshot
Table 146. New Compounding Pharma: Operating Segments
Table 147. New Compounding Pharma: Product Portfolio
Table 148. New Compounding Pharma: Net Sales
Table 149. New Compounding Pharma: Key Stratergies
Table 150. Olympia Compounding Pharmacy: Company Snapshot
Table 151. Olympia Compounding Pharmacy: Operating Segments
Table 152. Olympia Compounding Pharmacy: Product Portfolio
Table 153. Olympia Compounding Pharmacy: Net Sales
Table 154. Olympia Compounding Pharmacy: Key Stratergies
Table 155. Panacea Biomatx Inc (Triangle Compounding Pharmacy): Company Snapshot
Table 156. Panacea Biomatx Inc (Triangle Compounding Pharmacy): Operating Segments
Table 157. Panacea Biomatx Inc (Triangle Compounding Pharmacy): Product Portfolio
Table 158. Panacea Biomatx Inc (Triangle Compounding Pharmacy): Net Sales
Table 159. Panacea Biomatx Inc (Triangle Compounding Pharmacy): Key Stratergies
Table 160. Pencol Compounding Pharmacy: Company Snapshot
Table 161. Pencol Compounding Pharmacy: Operating Segments
Table 162. Pencol Compounding Pharmacy: Product Portfolio
Table 163. Pencol Compounding Pharmacy: Net Sales
Table 164. Pencol Compounding Pharmacy: Key Stratergies
Table 165. Perrigo Company plc (Fagron): Company Snapshot
Table 166. Perrigo Company plc (Fagron): Operating Segments
Table 167. Perrigo Company plc (Fagron): Product Portfolio
Table 168. Perrigo Company plc (Fagron): Net Sales
Table 169. Perrigo Company plc (Fagron): Key Stratergies
Table 170. Rx Express Compounding Pharmacy: Company Snapshot
Table 171. Rx Express Compounding Pharmacy: Operating Segments
Table 172. Rx Express Compounding Pharmacy: Product Portfolio
Table 173. Rx Express Compounding Pharmacy: Net Sales
Table 174. Rx Express Compounding Pharmacy: Key Stratergies
Table 175. Rx3 Compounding Pharmacy: Company Snapshot
Table 176. Rx3 Compounding Pharmacy: Operating Segments
Table 177. Rx3 Compounding Pharmacy: Product Portfolio
Table 178. Rx3 Compounding Pharmacy: Net Sales
Table 179. Rx3 Compounding Pharmacy: Key Stratergies
Table 180. Valor Compounding Pharmacy: Company Snapshot
Table 181. Valor Compounding Pharmacy: Operating Segments
Table 182. Valor Compounding Pharmacy: Product Portfolio
Table 183. Valor Compounding Pharmacy: Net Sales
Table 184. Valor Compounding Pharmacy: Key Stratergies
List of Figures
Figure 1. Compounding Pharmacies Market Segmentation
Figure 2. Compounding Pharmacies Market,2021-2031
Figure 3. Compounding Pharmacies Market,2021-2031
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Compounding Pharmacies Market:Drivers, Restraints and Opportunities
Figure 12. Compounding Pharmacies Market,By Therapeutic Area,2021(%)
Figure 13. Comparative Share Analysis of Pain Management Compounding Pharmacies Market,2021-2031(%)
Figure 14. Comparative Share Analysis of Hormone Replacement Therapy Compounding Pharmacies Market,2021-2031(%)
Figure 15. Comparative Share Analysis of Dermal Disorders Compounding Pharmacies Market,2021-2031(%)
Figure 16. Comparative Share Analysis of Nutritional Supplements Compounding Pharmacies Market,2021-2031(%)
Figure 17. Comparative Share Analysis of Others Compounding Pharmacies Market,2021-2031(%)
Figure 18. Compounding Pharmacies Market,By Route of Administration,2021(%)
Figure 19. Comparative Share Analysis of Oral Compounding Pharmacies Market,2021-2031(%)
Figure 20. Comparative Share Analysis of Topical Compounding Pharmacies Market,2021-2031(%)
Figure 21. Comparative Share Analysis of Others Compounding Pharmacies Market,2021-2031(%)
Figure 22. Compounding Pharmacies Market,By Sterility,2021(%)
Figure 23. Comparative Share Analysis of Non-Sterile Compounding Drugs Compounding Pharmacies Market,2021-2031(%)
Figure 24. Comparative Share Analysis of Sterile Compounding Drugs Compounding Pharmacies Market,2021-2031(%)
Figure 25. Compounding Pharmacies Market by Region,2021
Figure 26. U.S. Compounding Pharmacies Market,2021-2031($Million)
Figure 27. Canada Compounding Pharmacies Market,2021-2031($Million)
Figure 28. Mexico Compounding Pharmacies Market,2021-2031($Million)
Figure 29. Germany Compounding Pharmacies Market,2021-2031($Million)
Figure 30. France Compounding Pharmacies Market,2021-2031($Million)
Figure 31. Uk Compounding Pharmacies Market,2021-2031($Million)
Figure 32. Italy Compounding Pharmacies Market,2021-2031($Million)
Figure 33. Spain Compounding Pharmacies Market,2021-2031($Million)
Figure 34. Rest of Europe Compounding Pharmacies Market,2021-2031($Million)
Figure 35. Japan Compounding Pharmacies Market,2021-2031($Million)
Figure 36. China Compounding Pharmacies Market,2021-2031($Million)
Figure 37. India Compounding Pharmacies Market,2021-2031($Million)
Figure 38. Australia Compounding Pharmacies Market,2021-2031($Million)
Figure 39. South Korea Compounding Pharmacies Market,2021-2031($Million)
Figure 40. Rest of Asia-Pacific Compounding Pharmacies Market,2021-2031($Million)
Figure 41. Brazil Compounding Pharmacies Market,2021-2031($Million)
Figure 42. Saudi Arabia Compounding Pharmacies Market,2021-2031($Million)
Figure 43. South Africa Compounding Pharmacies Market,2021-2031($Million)
Figure 44. Rest of LAMEA Compounding Pharmacies Market,2021-2031($Million)
Figure 45. Top Winning Strategies, by Year
Figure 46. Top Winning Strategies, by Development
Figure 47. Top Winning Strategies, by Company
Figure 48. Product Mapping of Top 10 Players
Figure 49. Competitive Dashboard
Figure 50. Competitive Heatmap of Top 10 Key Players
Figure 51. Advanced Pharmacy.: Net Sales ,($Million)
Figure 52. Athenex Pharma Solutions.: Net Sales ,($Million)
Figure 53. B. Braun Melsungen AG.: Net Sales ,($Million)
Figure 54. Dougherty's Pharmacy, Inc..: Net Sales ,($Million)
Figure 55. Fresenius SE and Co. KGaA.: Net Sales ,($Million)
Figure 56. Institutional Pharmacy Solutions.: Net Sales ,($Million)
Figure 57. Itc Compounding Pharmacy.: Net Sales ,($Million)
Figure 58. Mcguff Companies, Inc..: Net Sales ,($Million)
Figure 59. Nephron Pharmaceuticals.: Net Sales ,($Million)
Figure 60. New Compounding Pharma.: Net Sales ,($Million)
Figure 61. Olympia Compounding Pharmacy.: Net Sales ,($Million)
Figure 62. Panacea Biomatx Inc (Triangle Compounding Pharmacy).: Net Sales ,($Million)
Figure 63. Pencol Compounding Pharmacy.: Net Sales ,($Million)
Figure 64. Perrigo Company PLC (Fagron).: Net Sales ,($Million)
Figure 65. Rx Express Compounding Pharmacy.: Net Sales ,($Million)
Figure 66. Rx3 Compounding Pharmacy.: Net Sales ,($Million)
Figure 67. Valor Compounding Pharmacy.: Net Sales ,($Million)

Executive Summary

According to the report, titled, “Compounding Pharmacies Market," the compounding pharmacies market was valued at $8.12 billion in 2021, and is estimated to reach $14.84 billion by 2031, growing at a CAGR of 6.2% from 2022 to 2031.

Compounding is the creation of a pharmaceutical preparation of a drug by a licensed pharmacist to meet the unique needs of an individual patient, when a commercially available drug does not meet those needs. While most pharmacies offer some level of compounding, most compounding is done in pharmacies that have made the investment in equipment and training to do so safely and efficiently. The preparations offered by these compounding pharmacies can be nonsterile (ointments, creams, liquids, or capsules that are used in areas of the body where absolute sterility is not necessary) or sterile (usually intended for the eye, or injection into body tissues or the blood). All licensed pharmacists learn during their training and education to perform basic compounding. In addition, most pharmacies have some compounding tools, such as a mortar and pestle for grinding materials, graduated cylinders for measuring liquids, balances for weighing solids, spatulas for mixing materials, and ointment slabs on which to work. With such tools and through applying their knowledge, all pharmacists routinely prepare nonsterile compounded preparations when requested by prescribers.

The key factors that drive the growth of the compounding pharmacies market size is increase in prevalence of chronic disease. high adoption of non-sterile medication, increase in old age population and improved life expectancy. In addition, growing drug failure rate, increase in popularity of personalized medicine and massive drug shortage across the globe are some compounding pharmacies market trends further expected to boost the market growth during forecast period. However, increase in restrictions on manufacturing of complex formulation is likely to hamper the growth of the compounding pharmacies market during the forecast period. Conversely, growth potential of emerging economies is expected to provide numerous opportunities for market growth during the forecast period.

By therapeutic area, the pain management segment dominated the market in 2021 and is expected to remain dominant during the forecast period. This is attributed to increase in number of geriatric populations, rise in number of surgical procedures and rise in healthcare expenditure. On the other side, others segment is projected to exhibit the fastest market growth during the forecast period, owing to rise in prevalence of neurological disorders, cancer cases.

Depending on route of administration, the oral segment dominated market in 2021 and is expected to remain dominant during the forecast period, owing to huge availability of various medicine that are meant to be orally administered. the oral administration of medicine is most common and the easier way of administering drugs since centuries. Furthermore, the others segment is projected to show fastest growth during the forecast period, owing to increase in product affordability, increase in geriatric population and rising acceptance among the customer regarding the compounding medications further boost the compounding pharmacies market growth.

By sterility, the non-sterile compounding drugs segment dominated the market in 2021 and is expected to remain dominant during the forecast period, in addition this segment is projected to show fastest growth during the forecast period, due to increase in prevalence of chronic disease such as diabetics, rising demand for personalized medicines and increase in geriatric population.

Region wise, North America has the highest compounding pharmacies market share share in compounding pharmacies industry in 2021 registering a CAGR of 5.9% during the forecast period. This is attributed to the well-established healthcare system, increase in number of geriatric patients, and supportive reimbursement policies in healthcare system and increasing number of healthcare facilities offering compounding pharmacy products. Asia pacific is projected to register the highest CAGR of 7.3% during the forecast period. The presence of a large population base, increasing per capita income, growing medical tourism industry, and rising public awareness regarding benefits of compounding medications are the key driving factors that boost the growth of the market in the region.

Key Findings of the Study

  • On the basis of therapeutic area, the pain management segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
  • On the basis of route of administration, the oral segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
  • Depending on sterility, non-sterile compounding drugs segment is projected to grow at a CAGR of 6.5% during the forecast period.
  • Region-wise, North America garnered the largest revenue share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR 7.3% during the forecast period.

Companies Mentioned

  • Advanced Pharmacy
  • Athenex Pharma Solutions
  • B. Braun Melsungen AG
  • Dougherty's Pharmacy, Inc.
  • Fresenius Se and Co. Kgaa
  • Institutional Pharmacy Solutions
  • Itc Compounding Pharmacy
  • Mcguff Companies, Inc.
  • Nephron Pharmaceuticals
  • New Compounding Pharma
  • Olympia Compounding Pharmacy
  • Panacea Biomatx Inc (Triangle Compounding Pharmacy)
  • Pencol Compounding Pharmacy
  • Perrigo Company plc (Fagron)
  • Rx Express Compounding Pharmacy
  • Rx3 Compounding Pharmacy
  • Valor Compounding Pharmacy

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Related Topics

Related Reports

Sterile Compounding Pharmacies Global Market Report 2024 - Product Image

Sterile Compounding Pharmacies Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Compounding Pharmacy Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F - Product Image

Compounding Pharmacy Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F

  • Report
  • 183 Pages
  • Global
From
Compounding Pharmacies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Compounding Pharmacies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 245 Pages
  • Global
Compounding Pharmacy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Compounding Pharmacy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 110 Pages
  • Global
From
Compounding Pharmacy - Global Strategic Business Report - Product Image

Compounding Pharmacy - Global Strategic Business Report

  • Report
  • 187 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.